gastric cancer

[Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences] Scientists summarize the current knowledge of the role of CD133 expression in gastic cancer and aim to contribute at identifying promising new strategies for treatment and management of gastric cancer.

[Oncogenesis] Researchers showed that the expression of EDDM3A was significantly upregulated in gastric cancer tissues and its upregulation correlates with poorer survival in patients with gastric cancer.

[Scientific Reports] Scientists explored the role of cancer cell-derived amphoterin-induced gene and open reading frame 2 (AMIGO2)-containing extracellular vesicles in the adhesion of cancer cells to human hepatic sinusoidal endothelial cells.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.

[Communications Biology] Researchers utilized an antigen-independent strategy for circulating tumor cell (CTC) isolation from metastatic gastric cancer patients involving a size-dependent recovery of CTCs and a single cell isolation technique.

[Cell Death & Disease] Scientists found that linc01133 was significantly upregulated in gastric cancer tissues compared to non-tumorous gastric tissues. Linc01133 over-expression significantly correlated with tumor size and tumor differentiation in gastric cancer patients.